Is Arrowhead Pharmaceuticals a Buy?
After years of struggling to deliver on its promise, RNA interference (RNAi) finally appears poised for commercial success. The gene-silencing technique was developed decades ago to tune the expression of genes that drive or protect against disease, but a string of clinical failures left investors scratching their heads. That's all changed thanks to the recent invention of targeted delivery technologies, which has reinvigorated interest in the genetic medicine approach.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) is one company taking advantage of recent scientific advances. The development-stage biopharma has formed drug partnerships with two global leaders, grown its pipeline to 11 unique programs, and engineered targeted delivery technologies for three tissue types.
Of course, much of the early stage company's potential exists solely on paper at the moment. That means much of the pharma stock's premium value is based on hope of future success. Should investors consider Arrowhead Pharmaceuticals a buy?
Source Fool.com
